{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T02:29:57Z","timestamp":1794623397868,"version":"4.9.1"},"reference-count":25,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,3,8]],"date-time":"2021-03-08T00:00:00Z","timestamp":1615161600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The American Journal of Emergency Medicine"],"published-print":{"date-parts":[[2021,8]]},"DOI":"10.1016\/j.ajem.2021.03.005","type":"journal-article","created":{"date-parts":[[2021,3,8]],"date-time":"2021-03-08T22:09:25Z","timestamp":1615241365000},"page":"51-55","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":53,"special_numbering":"C","title":["Immune checkpoint inhibitor-associated myasthenia gravis, myositis, and myocarditis overlap syndrome"],"prefix":"10.1016","volume":"46","author":[{"given":"Demis N.","family":"Lipe","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elkin","family":"Galvis-Carvajal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"Rajha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adriana H.","family":"Wechsler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan","family":"Gaeta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"9","key":"10.1016\/j.ajem.2021.03.005_bb0005","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1038\/s41571-019-0218-0","article-title":"Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance","volume":"16","author":"Martins","year":"2019","journal-title":"Nat Rev Clin Oncol"},{"issue":"12","key":"10.1016\/j.ajem.2021.03.005_bb0010","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1001\/jamaoncol.2018.3923","article-title":"Fatal toxic effects associated with immune checkpoint inhibitors: a systematic review and meta-analysis","volume":"4","author":"Wang","year":"2018","journal-title":"JAMA Oncol"},{"issue":"16","key":"10.1016\/j.ajem.2021.03.005_bb0015","doi-asserted-by":"crossref","first-page":"1702","DOI":"10.1001\/jama.2018.13995","article-title":"Immune checkpoint inhibitor toxicity in 2018","volume":"320","author":"Johnson","year":"2018","journal-title":"JAMA."},{"key":"10.1016\/j.ajem.2021.03.005_bb0020","article-title":"Inflammatory myositis in cancer patients receiving immune checkpoint inhibitors","author":"Aldrich","year":"2020","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.ajem.2021.03.005_bb0025","first-page":"21","article-title":"Severe combined cardiac and neuromuscular toxicity from immune checkpoint blockade: an institutional case series","volume":"6","author":"Arora","year":"2020","journal-title":"Cardiooncology."},{"key":"10.1016\/j.ajem.2021.03.005_bb0030","first-page":"2539493","article-title":"Severe myositis, myocarditis, and myasthenia gravis with elevated anti-striated muscle antibody following single dose of Ipilimumab-Nivolumab therapy in a patient with metastatic melanoma","volume":"2019","author":"Fazel","year":"2019","journal-title":"Case Rep Immunol"},{"issue":"3","key":"10.1016\/j.ajem.2021.03.005_bb0035","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1159\/000479958","article-title":"Nivolumab-induced myocarditis concomitant with myasthenia gravis","volume":"10","author":"Fukasawa","year":"2017","journal-title":"Case Rep Oncol"},{"key":"10.1016\/j.ajem.2021.03.005_bb0040","first-page":"5126717","article-title":"The terrible triad of checkpoint inhibition: a case report of myasthenia gravis, myocarditis, and myositis induced by cemiplimab in a patient with metastatic cutaneous squamous cell carcinoma","volume":"2020","author":"Jeyakumar","year":"2020","journal-title":"Case Rep Immunol"},{"issue":"7","key":"10.1016\/j.ajem.2021.03.005_bb0045","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1111\/cas.12961","article-title":"Myasthenic crisis and polymyositis induced by one dose of nivolumab","volume":"107","author":"Kimura","year":"2016","journal-title":"Cancer Sci"},{"key":"10.1016\/j.ajem.2021.03.005_bb0050","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.lungcan.2019.06.015","article-title":"Fatal adverse events in two thymoma patients treated with anti-PD-1 immune check point inhibitor and literature review","volume":"135","author":"Konstantina","year":"2019","journal-title":"Lung Cancer"},{"key":"10.1016\/j.ajem.2021.03.005_bb0055","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.ensci.2018.11.023","article-title":"Concomitant myasthenia gravis, myositis, myocarditis and polyneuropathy, induced by immune-checkpoint inhibitors: a life-threatening continuum of neuromuscular and cardiac toxicity","volume":"14","author":"Rota","year":"2019","journal-title":"eNeurologicalSci."},{"key":"10.1016\/j.ajem.2021.03.005_bb0060","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.ejca.2018.10.025","article-title":"Presence of antibodies to striated muscle and acetylcholine receptor in association with occurrence of myasthenia gravis with myositis and myocarditis in a patient with melanoma treated with an anti-programmed death 1 antibody","volume":"106","author":"Shirai","year":"2019","journal-title":"Eur J Cancer"},{"issue":"1","key":"10.1016\/j.ajem.2021.03.005_bb0065","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1093\/jjco\/hyv158","article-title":"Acetylcholine receptor binding antibody-associated myasthenia gravis and rhabdomyolysis induced by nivolumab in a patient with melanoma","volume":"46","author":"Shirai","year":"2016","journal-title":"Jpn J Clin Oncol"},{"key":"10.1016\/j.ajem.2021.03.005_bb0070","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.jns.2019.02.023","article-title":"PD-1 inhibitor-associated severe myasthenia gravis with necrotizing myopathy and myocarditis","volume":"399","author":"So","year":"2019","journal-title":"J Neurol Sci"},{"issue":"11","key":"10.1016\/j.ajem.2021.03.005_bb0075","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1212\/WNL.0000000000004359","article-title":"Nivolumab-related myasthenia gravis with myositis and myocarditis in Japan","volume":"89","author":"Suzuki","year":"2017","journal-title":"Neurology."},{"issue":"1","key":"10.1016\/j.ajem.2021.03.005_bb0080","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1002\/iju5.12128","article-title":"Pembrolizumab-induced myasthenia gravis with myositis and presumable myocarditis in a patient with bladder cancer","volume":"3","author":"Todo","year":"2020","journal-title":"IJU Case Rep"},{"issue":"5","key":"10.1016\/j.ajem.2021.03.005_bb0085","doi-asserted-by":"crossref","first-page":"250","DOI":"10.21037\/atm.2020.01.79","article-title":"Myositis-myasthenia gravis overlap syndrome complicated with myasthenia crisis and myocarditis associated with anti-programmed cell death-1 (sintilimab) therapy for lung adenocarcinoma","volume":"8","author":"Xing","year":"2020","journal-title":"Ann Transl Med"},{"issue":"7","key":"10.1016\/j.ajem.2021.03.005_bb0090","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1161\/CIRCULATIONAHA.118.035898","article-title":"Immune checkpoint inhibitor-associated myositis: expanding the Spectrum of cardiac complications of the immunotherapy revolution","volume":"138","author":"Anquetil","year":"2018","journal-title":"Circulation."},{"issue":"16","key":"10.1016\/j.ajem.2021.03.005_bb0095","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1016\/j.jacc.2018.02.037","article-title":"Myocarditis in patients treated with immune checkpoint inhibitors","volume":"71","author":"Mahmood","year":"2018","journal-title":"J Am Coll Cardiol"},{"issue":"10124","key":"10.1016\/j.ajem.2021.03.005_bb0100","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1016\/S0140-6736(18)30533-6","article-title":"Increased reporting of fatal immune checkpoint inhibitor-associated myocarditis","volume":"391","author":"Moslehi","year":"2018","journal-title":"Lancet."},{"issue":"9","key":"10.1016\/j.ajem.2021.03.005_bb0105","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1001\/jamaneurol.2016.2032","article-title":"Clinical characteristics of patients with double-Seronegative myasthenia gravis and antibodies to Cortactin","volume":"73","author":"Cortes-Vicente","year":"2016","journal-title":"JAMA Neurol"},{"issue":"5","key":"10.1016\/j.ajem.2021.03.005_bb0110","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1038\/nrneurol.2016.44","article-title":"Myasthenia gravis - autoantibody characteristics and their implications for therapy","volume":"12","author":"Gilhus","year":"2016","journal-title":"Nat Rev Neurol"},{"key":"10.1016\/j.ajem.2021.03.005_bb0115","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.ejca.2017.05.041","article-title":"Myasthenia gravis: an emerging toxicity of immune checkpoint inhibitors","volume":"82","author":"Makarious","year":"2017","journal-title":"Eur J Cancer"},{"issue":"2","key":"10.1016\/j.ajem.2021.03.005_bb0120","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1161\/CIRCULATIONAHA.118.034497","article-title":"Myocarditis in the setting of Cancer therapeutics: proposed case definitions for emerging clinical syndromes in cardio-oncology","volume":"140","author":"Bonaca","year":"2019","journal-title":"Circulation."},{"issue":"17","key":"10.1016\/j.ajem.2021.03.005_bb0125","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1200\/JCO.2017.77.6385","article-title":"Management of Immune-Related Adverse Events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology clinical practice guideline","volume":"36","author":"Brahmer","year":"2018","journal-title":"J Clin Oncol"}],"container-title":["The American Journal of Emergency Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0735675721001911?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0735675721001911?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T15:52:43Z","timestamp":1760025163000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0735675721001911"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8]]},"references-count":25,"alternative-id":["S0735675721001911"],"URL":"https:\/\/doi.org\/10.1016\/j.ajem.2021.03.005","relation":{},"ISSN":["0735-6757"],"issn-type":[{"value":"0735-6757","type":"print"}],"subject":[],"published":{"date-parts":[[2021,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Immune checkpoint inhibitor-associated myasthenia gravis, myositis, and myocarditis overlap syndrome","name":"articletitle","label":"Article Title"},{"value":"The American Journal of Emergency Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ajem.2021.03.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}